Mass. General team identifies mechanisms behind resistance to FGFR inhibitor drug

Investigators at the Massachusetts General Hospital (MGH) Cancer Center have identified the first genetic mechanisms conferring acquired resistance to a promising group of targeted cancer drugs. In a paper appearing in the March issue of Cancer Discovery, the researchers describe finding novel resistance mechanisms in three patients receiving fibroblast growth factor receptor (FGFR) inhibitor treatment for a type of liver cancer. While many patients show impressive responses to this treatment, the appearance of new drug-resistant mutations in the FGFR gene as tumors progress- and even several different mutations within samples from individual patients - suggests the need for drugs that block multiple pathways to avoid the resumption of tumor progression.

"FGFR represents an important therapeutic target in many cancers," says lead author Lipika Goyal, MD, of the MGH Cancer Center. "Our findings may inform future strategies for detecting and inducing more durable responses in FGFR2 fusion-positive intrahepatic cholangiocarcinoma and possibly other cancers in which the FGFR pathway is being explored as a therapeutic target."

Cancers driven by that activate FGFR include certain tumors of the lung, breast, stomach and bladder. From 10 to 20 percent of cases of (ICC) - the second most common tumor originating in the liver - are thought to be driven by FGFR2 fusion mutations. An FGFR inhibitor called BGJ398 is currently in a phase 2 clinical trial for treatment of advanced ICC whose FGFR-driven cancers progressed after chemotherapy, and while preliminary data from the trial reported a significant response to treatment, as with most targeted therapies, inevitably develops.

The MGH team analyzed samples from three patients with FGFR2 fusion-positive ICC enrolled in the BGJ398 trial for whom treatment led to a 30 to 50 percent tumor reduction, followed by after four to eight months. Analysis of cell-free DNA (cfDNA) from blood samples taken before BGJ398 treatment and after tumor progression revealed that one to five new FGFR2 kinase domain mutations had developed in each patient. A common mutation that emerged in all three patients was FGFR2 V564F, a gatekeeper mutation which interferes with the binding of BGJ398 to the FGFR. The other mutations altered the conformation of FGFR2, leading to continuous signaling through the pathway.

Rapid autopsy samples from one patient who died after having disease progression on BGJ398 treatment revealed that different metastases harbored distinct FGFR2 mutations, thus demonstrating that multiple different mechanisms can confer resistance in individual patients. Treating BGJ398-resistant cell lines with several other FGFR inhibitors showed that other structurally distinct drugs in the same class may be able to overcome FGFR2 resistance mutations.

"As seen with the development of resistance to other targeted treatment drugs, the mechanisms we identified are heterogeneous, and different therapeutic approaches may be necessary to overcome those resistance mechanisms," says senior and co-corresponding author Andrew X. Zhu, MD, PhD, director of Liver Cancer Research at the MGH Cancer Center. "In addition to helping us understand why patients developed within months of beginning a rationally chosen targeted therapy, our findings also suggest that tumor biopsies may underestimate resistance mechanisms. Repeat analysis of cfDNA may provide a more comprehensive picture of the mechanisms at play."


Explore further

Study identifies how cancer cells may develop resistance to FGFR inhibitors

More information: Lipika Goyal et al, Polyclonal SecondaryMutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma, Cancer Discovery (2017). DOI: 10.1158/2159-8290.CD-16-1000
Journal information: Cancer Discovery

Citation: Mass. General team identifies mechanisms behind resistance to FGFR inhibitor drug (2017, March 23) retrieved 21 September 2020 from https://medicalxpress.com/news/2017-03-mass-team-mechanisms-resistance-fgfr.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments